Stock listing

NASDAQ:RLYB Rallybio Corporation Stock

Home listing (NASDAQ) of Rallybio Corporation

Follow Rallybio Corporation into a list and get an email when it puts out news.

Share price · NASDAQ:RLYB

$15.47 USD +0.21 (+1.4%)

Close on Nov 20, 2026

Past year +217.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$15.15 – $15.70 USDNov 20, 2026
Volume
50,485 sharesNov 20, 2026
Market cap
$83.29M USDAt the close on Nov 20, 2026 · price × 5.38M shares outstanding
52-week range
$3.67 – $17.57 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$311,369 USDMedian day 8,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Rallybio Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RLYB · Home$15.47 USD+0.21 (+1.4%)50,485$15.32$15.70$15.15$15.26Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RLYB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$15.47+0.21+1.4%$15.32$15.70$15.1550,485
$15.26-0.03-0.2%$15.29$15.37$15.0528,765
$15.29-0.135-0.9%$15.35$15.37$15.0744,032
$15.43-0.295-1.9%$15.79$15.98$15.0944,476
$15.72+0.07+0.4%$15.62$15.79$15.5010,932
$15.65-0.15-0.9%$15.89$15.89$15.5123,314
$15.80+0.04+0.3%$15.86$15.86$15.5044,474
$15.76+0.10+0.6%$15.66$15.76$15.3225,130
$15.66-0.09-0.6%$15.53$16.00$15.5325,930
$15.75+0.06+0.4%$15.73$15.85$15.5153,302
$15.69-0.21-1.3%$15.71$15.87$15.5921,861
$15.90+0.04+0.3%$16.07$16.17$15.4559,434
$15.86+0.10+0.6%$15.76$16.43$15.5045,759
$15.76+0.22+1.4%$15.91$16.23$15.5559,403
$15.54+0.13+0.8%$15.42$16.25$15.3061,712
$15.41-0.58-3.6%$15.88$16.28$15.2851,893
$15.99+0.06+0.4%$15.66$16.44$15.6622,375
$15.93-0.72-4.3%$16.46$16.46$15.5152,617
$16.65+0.01+0.1%$16.71$16.71$16.503,538
$16.64+0.24+1.5%$16.62$16.79$16.406,200
$16.40+0.18+1.1%$16.20$16.41$16.205,500
$16.22-0.16-1.0%$16.37$16.62$16.1613,600
$16.38+0.03+0.2%$16.48$16.48$16.36102,600
$16.35+0.07+0.4%$16.40$16.43$16.208,100
$16.28-0.495-3.0%$16.70$16.70$16.2037,100
$16.78-0.13-0.8%$16.88$16.88$16.623,200
$16.91+0.185+1.1%$16.79$16.91$16.745,300
$16.72-0.07-0.4%$16.72$16.91$16.695,200
$16.79-0.23-1.4%$16.88$17.08$16.756,000
$17.02+0.03+0.2%$17.05$17.22$16.956,900
$16.99+0.06+0.4%$16.75$17.04$16.757,900
$16.93-0.15-0.9%$16.91$17.04$16.807,500
$17.08+0.18+1.1%$16.87$17.08$16.801,900
$16.90-0.18-1.1%$16.99$17.12$16.824,600
$17.08+0.32+1.9%$16.69$17.22$16.697,900
$16.76-0.44-2.6%$17.16$17.16$16.767,100
$17.20-0.02-0.1%$17.24$17.24$16.936,000
$17.22+0.17+1.0%$16.90$17.24$16.6116,700
$17.05+0.43+2.6%$16.55$17.05$16.5516,100
$16.62+0.01+0.1%$16.80$17.07$16.627,000
$16.61-0.25-1.5%$16.74$16.75$16.616,800
$16.86-0.06-0.4%$16.66$16.86$16.615,300
$16.92-0.01-0.1%$16.85$17.11$16.727,600
$16.93-0.26-1.5%$17.14$17.14$16.617,900
$17.19+0.03+0.2%$17.16$17.20$16.9216,100
$17.16+0.07+0.4%$17.18$17.18$17.134,300
$17.09-0.13-0.8%$17.24$17.24$16.7117,800
$17.22+0.71+4.3%$16.49$17.22$16.4522,200
$16.51-0.365-2.2%$16.98$16.98$16.5014,300
$16.88+0.125+0.7%$16.75$16.88$16.706,600
$16.75-0.22-1.3%$16.80$17.06$16.716,100
$16.97+0.36+2.2%$16.52$17.05$16.509,000
$16.61-0.315-1.9%$16.97$16.97$16.617,000
$16.93+0.05+0.3%$16.75$17.01$16.754,200
$16.88-0.065-0.4%$16.66$17.09$16.662,500
$16.94+0.25+1.5%$16.65$17.26$16.6529,800
$16.69-0.10-0.6%$17.05$17.05$16.6711,200
$16.79-0.02-0.1%$16.68$17.05$16.5014,100
$16.81+0.05+0.3%$16.51$17.12$16.515,800
$16.76-0.12-0.7%$17.18$17.23$16.765,900
$16.88-0.0050.0%$16.95$17.03$16.753,700
$16.89+0.085+0.5%$16.81$17.03$16.647,444
$16.80-0.03-0.2%$16.54$16.86$16.546,681
$16.83+0.23+1.4%$16.76$16.95$16.556,900
$16.60-0.40-2.4%$16.78$16.98$16.5115,300

Splits

1 split · NASDAQ:RLYB · every price before a split is adjusted for it

DayRatioWhat
1-for-8Consolidation
Ticker
NASDAQ:RLYB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Rallybio Corporation news

Rallybio Corporation on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in the last 12 months · 91 in all · newest Nov 11, 2026 · oldest 2021
Decks
5 decks · latest Jun 1, 2026

Where Rallybio Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:RLYB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RLYBBOATSUnited StatesUSD

Valuation

EV/sales −17.1× against a median of 25.1×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$7.40M USD
P/E
3.1×
EV/sales
−17.1×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.9×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
0.58

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Rallybio Corporation · NASDAQ:RLYBUS$83.29M−US$7.40M3.1×−17.1×n/a0.9×n/a0.0×0.58
Formosa Pharmaceuticals, Inc. · TWSE:6838US$85.43MUS$48.52Mn/a30.4×n/a2.0×−361.4%0.0×n/a
Genome & Co. · KRX:314130US$85.27MUS$37.21Mn/a2.0×n/a1.6×−169.1%0.0×n/a
Anixa Biosciences, Inc. · NASDAQ:ANIXUS$84.82MUS$70.96Mn/an/an/a5.9×n/a0.0×1.45
BetterLife Pharma Inc. · CSE:BETRUS$84.03MUS$83.37Mn/an/an/an/an/an/a1.14
Shine-On Biomedical Co., Ltd. · TPEX:6926US$83.56MUS$59.02Mn/a64.8×n/a3.5×−367.6%0.0×n/a
TuHURA Biosciences, Inc. · NASDAQ:HURAUS$82.20MUS$89.50Mn/an/an/a4.3×n/a0.5×2.81
3D Medicines, Inc. · HKEX:1244US$81.88MUS$48.45Mn/a0.9×n/a1.0×−49.9%0.3×n/a
Kintor Pharmaceutical Ltd · HKEX:9939US$81.70MUS$96.94Mn/a19.8×n/a5.0×−612.3%1.2×n/a
Nkarta, Inc. · NASDAQ:NKTXUS$81.38M−US$75.22Mn/an/an/a0.4×n/a0.0×1.67
Captor Therapeutics SA · GPW:CTXUS$81.11MUS$64.15Mn/a130×n/a5.1×n/a0.0×n/a
Median of the othersUS$82.88MUS$61.59M25.1×3.5×−361.4%0.0×1.56

Forecasts

Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
8.00 USD · Analysts' mean
EPS, year to Dec 2026
-5.52 · 1 analyst

Team and board

Officers

OfficerRole
Steve UdenCo-Founder and Chief Executive Officer
Jonathan I. LieberChief Financial Officer
Hui LiuExecutive Vice President, Chief Business Officer and Head of US
Amanda HaywardExecutive Chairman of Hoba Therapeutics
Martin MackayCo-Founder and Chairman

Board

DirectorRole
Christine A. NashBoard Chair
Martin MackayCo-Founder and Chairman
Helen M. BoudreauBoard Member
Lucian IancoviciBoard Member
Paula SoteropoulosLead Independent Director
Rob HopfnerBoard Member
Ron HuntBoard Member
Wendy K. ChungBoard Member

Events

QuarterResultsShare move
Q3 2026Oct 27, 2026−4.0%
Q2 2026Aug 6, 2026 · Before open+0.3%
Q1 2026May 13, 2026 · After close−1.0%
Q4 2025Mar 17, 2026−0.5%
Q3 2025Nov 6, 2025 · Before open+2.2%
Q2 2025Aug 7, 2025 · Before open−3.2%
Q1 2025May 8, 2025 · Before open−2.5%
Q4 2024Mar 13, 2025−4.1%
Q3 2024Nov 7, 2024 · Before open−1.0%
Q2 2024Aug 8, 2024 · Before open−0.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+2.7%
Q4 2023Mar 12, 2024 · Before open−8.7%
Q3 2023Nov 9, 2023 · Before open+1.3%
Q2 2023Aug 8, 2023 · Before open−4.0%
Q1 2023May 9, 2023 · Before open−7.0%
Q4 2022Mar 6, 2023 · Before open+10.3%
Q3 2022Nov 7, 2022 · Before open+4.1%
Q2 2022Aug 8, 2022 · Before open−5.8%
Q1 2022May 10, 2022 · Before open+6.0%
Q4 2021Mar 15, 2022 · Before open−10.6%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (June 2026)Merger or acquisition30 slidesJun 1, 2026
Merger or Acquisition (March 2026)Merger or acquisition36 slidesMar 2, 2026
Corporate Update (December 2023)Corporate update6 slidesDec 20, 2023
31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2023Conference14 slidesJun 24, 2023
Investor Presentation (March 2022)Investor deck29 slidesMar 7, 2022

Open Decks

IPO

Priced at US$13.00 a share on Jul 28, 2021.

Price
US$13.00 a share
Shares offered
6,200,000 shares of common stock
Offering size
US$80.6 million
Underwriters' option
Up to 930,000 more shares
Underwriters
Jefferies, Cowen, Evercore ISI · In the order on the cover
Shares delivered
On or about Aug 2, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceApr 27, 2021
Filed publiclyJul 2, 2021
Amended onceJul 22, 2021
Declared effective by the SECJul 28, 2021
Shares registered with an exchangeJul 29, 2021
Final prospectus, with the priceJul 30, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue858.0K636.0K
Research and development19.6M41.5M53.5M40.7M26.9M17.6M
Operating income-33.1M-60.5M-78.9M-67.9M-45.6M-25.3M
Depreciation and amortization92.0K131.0K150.0K167.0K109.0K62.0K
EBITDA-33.0M-60.4M-78.8M-67.7M-45.5M-25.2M
Interest expense010.0K49.0K
Income before tax-8.98M-55.5M-72.5M-65.6M-45.5M-24.9M
Income tax00000-15.0K
Net income-8.98M-57.8M-74.6M-66.7M-47.0M-26.4M
Earnings per share, basic-1.59-10.61-1.84-2.09-1.84-1.52
Earnings per share, diluted-1.59-10.61-1.84-2.09-1.84-1.52

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents31.4M13.9M24.5M57.0M175.3M140.2M
Short-term investments23.4M51.6M85.4M112.0M0
Current assets61.3M67.8M114.8M179.5M180.9M141.3M
Property, plant and equipment23.0K115.0K246.0K385.0K511.0K287.0K
Total assets62.3M68.1M115.6M180.4M182.2M141.9M
Accounts payable126.0K278.0K976.0K1.11M603.0K1.58M
Current liabilities4.22M6.24M9.26M10.7M6.55M5.84M
Total liabilities4.30M6.45M9.44M11.1M6.58M5.86M
Shareholders' equity58.0M61.7M106.2M169.3M175.6M136.0M
Shares outstanding5.28M5.19M37.8M37.8M32.1M23.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-29.8M-49.3M-60.3M-57.3M-45.5M-22.0M
Capital spending0-12.0K-54.0K-333.0K-137.0K
Free cash flow-49.3M-60.3M-57.3M-45.9M-22.2M
Cash from investing47.3M33.5M27.7M-112.2M-2.33M-2.07M
Cash from financing16.0K5.20M143.0K51.1M83.0M144.9M
Change in cash17.5M-10.6M-32.5M-118.4M35.1M120.8M

Open Financials

Filings

FilingDateTypeFiled with
425Nov 12, 2026Other filingsSEC
8-K · Current reportNov 12, 2026Current reportSEC
425Nov 10, 2026Other filingsSEC
8-K · Current reportNov 10, 2026Current reportSEC
425Nov 6, 2026Other filingsSEC
8-K · Current reportNov 6, 2026Current reportSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
8-K · Current reportNov 4, 2026Management or board changeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 29, 2026Insider tradeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
10-Q · Quarterly reportOct 27, 2026Quarterly reportSEC
425Oct 26, 2026Other filingsSEC
8-K · Current reportOct 26, 2026Current reportSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveOct 16, 2026Other filingsSEC
424B3 · ProspectusOct 15, 2026Offer documentSEC
S-4/A · Registration statement, amendedOct 14, 2026Offer documentSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
S-4/A · Registration statement, amendedOct 2, 2026Offer documentSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
S-4/A · Registration statement, amendedSep 15, 2026Offer documentSEC
8-K · Current reportSep 9, 2026Management or board changeSEC
S-4/A · Registration statement, amendedAug 26, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 4, 2026Big-stake noticeSEC
S-4 · Registration statementJul 15, 2026Offer documentSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 5, 2026Big-stake noticeSEC
425Jun 1, 2026Other filingsSEC
8-K · Current reportJun 1, 2026Material contractSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
RW · Request to withdraw a registrationMay 5, 2026Other filingsSEC
8-K · Current reportMay 4, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
S-4/A · Registration statement, amendedApr 24, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 13, 2026Big-stake noticeSEC
8-K · Current reportMar 31, 2026Management or board changeSEC
S-4 · Registration statementMar 16, 2026Offer documentSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
3 · Initial statement of ownershipMar 10, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 6, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 3, 2026Big-stake noticeSEC
425Mar 2, 2026Other filingsSEC
8-K · Current reportMar 2, 2026Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 27, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportJan 29, 2026Meeting outcomeSEC
DEF 14A · Proxy statementJan 2, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 23, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportAug 29, 2025Current reportSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
8-K · Current reportJul 8, 2025Acquisition or disposalSEC
8-K · Current reportJun 27, 2025Management or board changeSEC
8-K · Current reportMay 16, 2025Meeting outcomeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMay 9, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
8-K · Current reportApr 8, 2025Current reportSEC
DEF 14A · Proxy statementApr 7, 2025Meeting noticeSEC
8-K · Current reportMar 13, 2025Current reportSEC
424B5 · ProspectusMar 13, 2025Offer documentSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
8-K · Current reportFeb 25, 2025Current reportSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
8-K · Current reportSep 17, 2024Management or board changeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
SC 13G · Big-stake noticeJul 30, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJul 30, 2024Big-stake noticeSEC
8-K · Current reportJul 23, 2024Management or board changeSEC
8-K · Current reportMay 21, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 21, 2024Other filingsSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
CORRESP · Letter to the SECMay 16, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 16, 2024Other filingsSEC
S-3 · Registration statementMay 10, 2024Offer documentSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
DApr 22, 2024Other filingsSEC
DEF 14A · Proxy statementApr 11, 2024Meeting noticeSEC
8-K · Current reportApr 10, 2024Material contractSEC
S-8 · Registration statement for employee plansMar 13, 2024Offer documentSEC
10-K · Annual reportMar 12, 2024Annual reportSEC
8-K · Current reportMar 12, 2024ResultsSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
8-K · Current reportFeb 6, 2024ResultsSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 2, 2024Big-stake noticeSEC
8-K · Current reportDec 20, 2023Current reportSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
8-K · Current reportJun 29, 2023Management or board changeSEC
8-K · Current reportMay 22, 2023Meeting outcomeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 15, 2023Other filingsSEC
424B3 · ProspectusMay 12, 2023Offer documentSEC
CORRESP · Letter to the SECMay 11, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 11, 2023Other filingsSEC
S-8 · Registration statement for employee plansMay 10, 2023Offer documentSEC
S-3 · Registration statementMay 9, 2023Offer documentSEC
10-Q · Quarterly reportMay 9, 2023Quarterly reportSEC
8-K · Current reportMay 9, 2023ResultsSEC
DEF 14A · Proxy statementApr 10, 2023Meeting noticeSEC
4 · Change in ownershipMar 16, 2023Insider tradeSEC
4 · Change in ownershipMar 9, 2023Insider tradeSEC
4 · Change in ownershipMar 9, 2023Insider tradeSEC
10-K · Annual reportMar 6, 2023Annual reportSEC
8-K · Current reportMar 6, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2023Insider tradeSEC
4 · Change in ownershipFeb 6, 2023Insider tradeSEC
4 · Change in ownershipFeb 6, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
3 · Initial statement of ownershipFeb 1, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 1, 2023Big-stake noticeSEC
8-K · Current reportJan 31, 2023Management or board changeSEC
SC 13G/A · Big-stake notice, amendedJan 23, 2023Big-stake noticeSEC
4 · Change in ownershipJan 5, 2023Insider tradeSEC
4 · Change in ownershipJan 5, 2023Insider tradeSEC
4 · Change in ownershipJan 5, 2023Insider tradeSEC
4 · Change in ownershipJan 5, 2023Insider tradeSEC
8-K · Current reportDec 1, 2022Current reportSEC
4 · Change in ownershipNov 17, 2022Insider tradeSEC
SC 13G · Big-stake noticeNov 17, 2022Big-stake noticeSEC
8-K · Current reportNov 14, 2022Material contractSEC

This page holds 200 of 314 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Rallybio Corporation’s releases

Common shares
5,383,937
Fully diluted
5,383,937

Fully diluted

LineShares
Common shares5,383,937

Share count over time

CountShares
Nov 22, 20265,383,937
Nov 11, 2026
Nov 10, 2026

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
ADAR1 Capital Management, LLC926K17.2%US$15.9MSep 30, 2026
Fidelity795K14.8%US$13.7MSep 30, 2026
Viking Global Investors LP524K9.7%US$9.02MSep 30, 2026
Tpg Gp A, LLC379K7.0%US$6.51MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC301K5.6%US$5.17MSep 30, 2026
Vanguard204K3.8%US$3.51MSep 30, 2026
Renaissance Technologies146K2.7%US$2.51MSep 30, 2026
Rangeley Capital, LLC97,9481.8%US$1.68MSep 30, 2026
Mariner, LLC50,5660.94%US$870KSep 30, 2026
Citadel47,7090.89%US$821KSep 30, 2026
All 30 holders
HolderSharesOf the companyValueAs of
Two Sigma43,1830.80%US$743KSep 30, 2026
Geode Capital33,9430.63%US$584KSep 30, 2026
BlackRock30,5570.57%US$526KSep 30, 2026
Jane Street22,5550.42%US$388KSep 30, 2026
Dimensional19,4580.36%US$335KSep 30, 2026
XTX Topco Ltd14,3380.27%US$247KSep 30, 2026
State Street12,9960.24%US$224KSep 30, 2026
Spark Investment Management LLC12,7000.24%US$218KSep 30, 2026
Morgan Stanley11,0480.21%US$190KSep 30, 2026
Acadian Asset Management LLC5,2770.10%US$90,000Sep 30, 2026
Hartford Financial Management Inc.8120.02%US$13,967Sep 30, 2026
RBC534<0.01%US$9,000Sep 30, 2026
Caitong International Asset Management Co., Ltd421<0.01%US$7,241Sep 30, 2026
JPMorgan320<0.01%US$5,510Sep 30, 2026
UBS269<0.01%US$4,627Sep 30, 2026
BNP Paribas120<0.01%US$2,064Sep 30, 2026
SBI Securities Co., Ltd.77<0.01%US$1,324Sep 30, 2026
Fortitude Family Office, LLC53<0.01%US$912Sep 30, 2026
Allworth Financial LP6<0.01%US$104Sep 30, 2026
Danske Bank A/S1<0.01%US$17Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund208K3.9%US$3MMay 31, 2026
Vanguard Total Stock Market Index Fund135K2.5%US$2.15MJun 30, 2026
Fidelity Growth Company K6 Fund56,5221.0%US$817KMay 31, 2026
Fidelity Series Growth Company Fund53,6001.00%US$775KMay 31, 2026
Vanguard Extended Market Index Fund32,4470.60%US$519KJun 30, 2026
Fidelity Extended Market Index Fund16,2520.30%US$235KMay 31, 2026
iShares Micro-Cap ETF11,8320.22%US$189KJun 30, 2026
Dimensional U.S. Small Cap ETF6,6750.12%US$106KJul 31, 2026
U.S. Micro Cap Portfolio4,6050.09%US$73,358Jul 31, 2026
Fidelity Series Total Market Index Fund4,5080.08%US$65,186May 31, 2026
All 16 holders
HolderSharesOf the companyValueAs of
Fidelity Total Market Index Fund4,0790.08%US$58,982May 31, 2026
Vanguard Institutional Total Stock Market Index Fund3,1410.06%US$50,256Jun 30, 2026
Fidelity Nasdaq Composite Index Fund3,0030.06%US$43,423May 31, 2026
Vanguard Balanced Index Fund2,2890.04%US$36,624Jun 30, 2026
1290 VT Micro Cap Portfolio7950.01%US$12,720Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF5780.01%US$9,208Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Lieber Jonathan I
Officer: Chief Financial Officer
Sale599USD 16.04US$9,608Oct 27, 2026
ADAR1 Capital Management, LLC
10% owner
Buy10,000USD 13.98US$140KMay 19, 2026
ADAR1 Capital Management, LLC
10% owner
Buy200USD 13.80US$2,760May 19, 2026
ADAR1 Capital Management, LLC
10% owner
Buy6,009USD 13.98US$84,006May 18, 2026
Schneeberger Daniel
10% owner
Buy100USD 13.80US$1,380May 15, 2026
Schneeberger Daniel
10% owner
Buy200USD 13.95US$2,790May 15, 2026
Schneeberger Daniel
10% owner
Buy4,081USD 13.80US$56,318May 13, 2026
Schneeberger Daniel
10% owner
Buy75,178USD 14.00US$1.05MMay 13, 2026
ADAR1 Capital Management, LLC
10% owner
Buy800USD 13.83US$11,064May 12, 2026
ADAR1 Capital Management, LLC
10% owner
Buy5,100USD 14.00US$71,400May 11, 2026
All 15 trades
TradeTradeSharesPriceValueDate
ADAR1 Capital Management, LLC
10% owner
Buy25,000USD 14.00US$350KMay 11, 2026
ADAR1 Capital Management, LLC
10% owner
Buy19,900USD 14.00US$279KMay 11, 2026
Schneeberger Daniel
10% owner
Buy35,101USD 14.00US$491KMay 5, 2026
Schneeberger Daniel
10% owner
Buy3,900USD 13.90US$54,210May 4, 2026
Schneeberger Daniel
10% owner
Buy116,904USD 13.97US$1.63MMay 4, 2026

Big stakes

StakeStakeSharesDateFiling
ADAR1 Capital Management, LLC17.50%926KMay 31, 2026Schedule 13G
FMR LLC15.00%795KJun 30, 2026Schedule 13G
Viking Global Investors LP9.99%529KMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Martin Mackay
Other companies: Kailera Therapeutics, Inc. (Co-Founder and Chair of Board, Rallybio Corporation · Since at least Apr 16, 2026); SpringWorks Therapeutics Inc (Director · Since at least Jul 29, 2024); Charles River Laboratories International, Inc. (Director · Since at least Jul 1, 2017); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & Global Head of R&D · May 13, 2013 – Feb 27, 2017 · Past); Pfizer, Inc. (Senior Vice President · Sep 30, 2008 – May 14, 2010 · Past)
Co-Founder and Chairman · Since at least Jul 28, 2021
Timothy M Shannon
Other companies: IDEAYA Biosciences, Inc. (Director · May 22, 2019 – Jun 7, 2023 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 13, 2019 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Nov 29, 2016 · Past); Celldex Therapeutics, Inc. (Director · Oct 1, 2009 – Jun 4, 2014 · Past); Curagen Corp (Former President and CEO, Director · May 25, 2007 – Oct 1, 2009 · Past)
Director · Jul 28, 2021 – Jan 3, 2022 · Past
Helen M. Boudreau
Other companies: Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Tvardi Therapeutics, Inc. (Director · Aug 2, 2023 – Jun 4, 2024 · Past); Kineta Inc. (Chief Financial Officer · Feb 10, 2016 – Mar 1, 2018 · Past)
Board Member · Since at least Jul 29, 2021
Lucian Iancovici
Other companies: Achieve Life Sciences, Inc. (Chairman of the Board of Directors · Since at least Apr 17, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); CeriBell, Inc. (Director · Oct 10, 2024 – Oct 10, 2024 · Past)
Board Member · Since at least Jul 29, 2021
Steven Ryder
Other companies: MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Reata Pharmaceuticals Inc (Director · Jul 11, 2022 – Sep 26, 2023 · Past)
Chief Medical Officer · Jul 29, 2021 – Feb 14, 2025 · Past
Jonathan I. Lieber
Other companies: Decoy Therapeutics Inc. (Director · Since at least Jun 7, 2022)
Chief Financial Officer · Since at least Feb 1, 2023
Paula Soteropoulos
Other companies: Dianthus Therapeutics, Inc. (Director · Since at least May 22, 2025)
Lead Independent Director · Since at least May 13, 2025
Wendy Chung
Other companies: Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022)
Board Member · Since at least Aug 1, 2022
Amanda HaywardExecutive Chairman of Hoba Therapeutics · Since at least Nov 4, 2026
Christine A. NashDirector · Since at least Apr 4, 2022
All 19 people
PersonSeat
David BejkerCEO · Jun 13, 2025 – Nov 4, 2026 · Past
Hui LiuExecutive Vice President, Chief Business Officer and Head of US · Since at least Sep 24, 2026
Peter ZerhouniCFO and CBO · Jun 13, 2025 – Nov 4, 2026 · Past
Robert Lorne HopfnerDirector · Since at least Oct 12, 2026
Rob HopfnerBoard Member · Since at least Oct 14, 2026
Ronald HuntDirector · Since at least Oct 29, 2026
Ron HuntBoard Member · Since at least Nov 2, 2026
Stephen UdenChief Executive Officer, Director · Since at least Jul 28, 2021
Steve UdenCo-Founder and Chief Executive Officer · Since at least Oct 29, 2026

Open People

Log in to ask 6ix AI your own questions about Rallybio Corporation.